References
Penning TD, Talley JJ, Bertenshaw SR, Carter JS, Collins PW, Docter S et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1 h-pyrazol-1-yl]benzenesulfonamide (sc-58635, celecoxib). J Med Chem. 1997;40:1347–65.
Choi SH, Langenbach R, Bosetti F. Genetic deletion or pharmacological inhibition of cyclooxygenase-1 attenuate lipopolysaccharide-induced inflammatory response and brain injury. FASEB J. 2008;22:1491–501.
Teng XW, Abu-Mellal AKM, Davies NM. Formulation dependent pharmacokinetics, bioavailability and renal toxicity of a selective cyclooxygenase-1 inhibitor SC-560 in the rat. J Pharm Pharm Sci. 2003;6:205–10.
Long S, Theiss KL, Li T, Loftin CD. Cyclooxygenase-1-selective inhibitor sc-560. Acta Cryst. 2009;E65:o360.
Acknowledgment
We are thankful for the financial support by NSF (DMR-0449633).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Long, S., Theiss, K.L., Mattei, A. et al. Solid-State Properties of the Cyclooxygenase-1-Selective Inhibitor, SC-560. AAPS PharmSciTech 11, 485–488 (2010). https://doi.org/10.1208/s12249-010-9407-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1208/s12249-010-9407-y